JP2022507373A5 - - Google Patents

Info

Publication number
JP2022507373A5
JP2022507373A5 JP2021526247A JP2021526247A JP2022507373A5 JP 2022507373 A5 JP2022507373 A5 JP 2022507373A5 JP 2021526247 A JP2021526247 A JP 2021526247A JP 2021526247 A JP2021526247 A JP 2021526247A JP 2022507373 A5 JP2022507373 A5 JP 2022507373A5
Authority
JP
Japan
Prior art keywords
cancer
polypeptide
composition according
seq
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526247A
Other languages
English (en)
Japanese (ja)
Other versions
JP7611137B2 (ja
JP2022507373A (ja
Filing date
Publication date
Priority claimed from GBGB1818576.9A external-priority patent/GB201818576D0/en
Application filed filed Critical
Publication of JP2022507373A publication Critical patent/JP2022507373A/ja
Publication of JP2022507373A5 publication Critical patent/JP2022507373A5/ja
Application granted granted Critical
Publication of JP7611137B2 publication Critical patent/JP7611137B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526247A 2018-11-14 2019-11-14 免疫原性アルギナーゼ2ポリペプチド Active JP7611137B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1818576.9A GB201818576D0 (en) 2018-11-14 2018-11-14 Arginase 2 polypeptides
GB1818576.9 2018-11-14
PCT/EP2019/081369 WO2020099582A1 (en) 2018-11-14 2019-11-14 Immunogenic arginase 2 polypeptides

Publications (3)

Publication Number Publication Date
JP2022507373A JP2022507373A (ja) 2022-01-18
JP2022507373A5 true JP2022507373A5 (cg-RX-API-DMAC7.html) 2022-08-30
JP7611137B2 JP7611137B2 (ja) 2025-01-09

Family

ID=64739444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526247A Active JP7611137B2 (ja) 2018-11-14 2019-11-14 免疫原性アルギナーゼ2ポリペプチド

Country Status (11)

Country Link
US (2) US12234288B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880225A1 (cg-RX-API-DMAC7.html)
JP (1) JP7611137B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210093287A (cg-RX-API-DMAC7.html)
CN (1) CN113164545B (cg-RX-API-DMAC7.html)
AU (1) AU2019378076B2 (cg-RX-API-DMAC7.html)
CA (1) CA3118794A1 (cg-RX-API-DMAC7.html)
GB (1) GB201818576D0 (cg-RX-API-DMAC7.html)
IL (1) IL283133B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202104881VA (cg-RX-API-DMAC7.html)
WO (1) WO2020099582A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
GB201912030D0 (en) * 2019-08-21 2019-10-02 Cancer Research Tech Ltd Binding molecules
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
US20250161422A1 (en) 2022-02-24 2025-05-22 Io Biotech Aps Arginase 2 vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US20070014801A1 (en) * 2001-01-24 2007-01-18 Gish Kurt C Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP1474528A4 (en) * 2000-10-13 2006-06-14 Protein Design Labs Inc METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS
PL3064579T3 (pl) * 2008-10-31 2021-07-05 Aerase, Inc. Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz
CA3172682A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
HUE064857T2 (hu) 2016-03-04 2024-04-28 Io Biotech Aps Kombinációs terápia a rák ellen
ES2909556T3 (es) 2016-08-08 2022-05-09 Aerase Inc Composiciones y procedimientos para el tratamiento de cáncer con agentes de disminución de arginina y de inmunoncología
PL3522905T3 (pl) * 2016-10-07 2025-01-07 Io Biotech Aps Immunogenne peptydy arginazowe
GB201815549D0 (en) 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides

Similar Documents

Publication Publication Date Title
KR100767554B1 (ko) 암 억제 유전자 더블유티1의 생산물에 기초한 암항원
JP2022095926A (ja) 乳癌再発の予防のためのワクチン
RU2011108315A (ru) Индуцирующий иммунитет агент
JP2022535102A5 (cg-RX-API-DMAC7.html)
JPWO2000006602A1 (ja) 癌抑制遺伝子wt1の産物に基づく癌抗原
JP2024513559A5 (cg-RX-API-DMAC7.html)
JP2008530975A5 (cg-RX-API-DMAC7.html)
EP1469869B1 (en) Peptide useful in immunomodulation
RU2011110376A (ru) Эпитопные пептиды hig2 и urlc10 и содержание их вакцины
AU2013249522A1 (en) Multivalent breast cancer vaccine
CN112203663A (zh) Cpg两亲分子及其用途
JP2018509423A5 (cg-RX-API-DMAC7.html)
CN101754768A (zh) 用作癌症疫苗的存活蛋白肽
JP2022501046A5 (cg-RX-API-DMAC7.html)
US20140220074A1 (en) Toll-Like Receptor 4 (Tlr-4) Agonist Peptides For Modulating Tlr-4 Mediated Immune Response
CA2432971A1 (en) Polypeptides
WO2017177910A1 (zh) 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物
ES2390967T3 (es) Epítopo/péptido reconocido por LTC específico para Ep-CAM con restricción por ALH-A2402 y su utilización
CN111118063B (zh) 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用
US8207141B2 (en) Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
JP2007511534A5 (cg-RX-API-DMAC7.html)
CN102838679A (zh) Her2-neu抗原阳性肿瘤治疗性疫苗的制备及应用
JP2015525785A (ja) 腫瘍治療のためのペプチドEGFRvIII配列に基づくワクチン
JP2025508840A5 (cg-RX-API-DMAC7.html)
US20260022390A1 (en) Recombinant expression vector for melittin secretion and attenuated salmonella strain transformed therewith